Buy & Sell Fiverr International Ltd (FVRR) – Fiverr International Ltd Price Today
Aura AI Summary
Key Stats
- $358.07MMarket Cap
- IndustrialsSector
- -18.85%3M Drawdown
- $88.67MEnterprise Value
- -Dividend Yield
- 59 daysTypical Hold Time
Fiverr International Ltd (FVRR) is currently valued at a market capitalization of $358.07M, with an enterprise value of $88.67M. Over the past 52 weeks, Fiverr International Ltd has traded between a low of $9.76 and a high of $29.88, highlighting its annual price range. Over the past three months, Fiverr International Ltd has recorded a drawdown of -18.85%, reflecting recent price volatility. On average, investors hold Fiverr International Ltd for approximately 59 days, indicating typical investor behavior on the platform.
About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Most Recent News
Harvest Investment Services sells 356,000 shares of Adaptive Biotechnologies worth $5.7M
Harvest Investment Services has sold 356,000 shares of Adaptive Biotechnologies, totaling approximately $5.7 million. This significant sale may impact the stock's market perception and price. Investors should watch for any further moves by major shar...

Harbour BioMed wins $20.2M patent infringement verdict against Amgen, with potential damages tripling to $60.6M.
Harbour BioMed secured a unanimous jury verdict in Delaware, finding Amgen willfully infringed on its antibody discovery patent, awarding $20.2 million in damages. The verdict validates Harbour's proprietary technology and allows the company to seek ...

Ascentage Pharma reveals promising clinical data for olverembatinib and lisaftoclax in blood cancer treatments at EHA2026.
Ascentage Pharma presented 17 clinical updates on its key cancer drugs olverembatinib and lisaftoclax at the EHA2026 Congress, showing strong efficacy and safety in treating various blood cancers including chronic myeloid leukemia (CML) and Philadelp...
